永安药业董事长 解除留置恢复履职

Core Viewpoint - The chairman of Yong'an Pharmaceutical, Chen Yong, has had his detention lifted after approximately four months, allowing him to resume his duties, while the company continues to operate normally [1] Company Overview - Yong'an Pharmaceutical is a leading player in the taurine industry, holding around 50% of the global market share and serving major clients such as Nestlé and Coca-Cola [1] Financial Performance - In the first half of 2025, Yong'an Pharmaceutical reported revenue of 367.4 million yuan, a year-on-year decline of 13.72% - The net profit for the same period was 12.5 million yuan, down 76.19% compared to the previous year [1] Market Conditions - The company's performance has been adversely affected by a sluggish market, leading to decreases in both the production volume and sales price of its main product, taurine [1] Competitive Advantages - Yong'an Pharmaceutical claims to have competitive advantages in price, quality, and brand due to its proprietary production processes and multiple patents [1] - The management has indicated a commitment to enhancing core technology development to strengthen its competitive position [1]